Capital Structure Models and Contingent Convertible Securities
Risks · 18.03.2024 · 12 (3) · 55
DOI: 10.3390/risks12030055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Risks, online erschienen am 18.03.2024. Verfasst von Di Meng und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CANSSI-CRT, Wilfrid Laurier University, NSERC.
Abstract (Originalsprache)
We implemented a methodology to calibrate capital structure models for banks that have issued contingent convertible securities (CoCos). Typical studies involving capital structure model calibration focus on non-financial firms as they have lower leverage and no contingent convertible securities. From a theoretical perspective, we found that jumps in the asset value process were necessary to obtain a satisfactory fit to the market data. In practice, contingent capital conversion triggers are discretionary, and there is considerable uncertainty around when regulators are likely to enforce conversion. The market-implied conversion triggers we obtain indicate that the market expects regulators to enforce conversion while the issuing bank is a going concern, as opposed to a gone concern. This fact is presumably of interest to potential dealers, regulators, issuers, and investors.
Förderung
- CANSSI-CRT
- Wilfrid Laurier University
- NSERC
- Research Support Fund
Zitieren
APA
Meng, D., Metzler, A., & Reesor, R. M. (2024). Capital Structure Models and Contingent Convertible Securities. Risks, 12(3), 55. https://doi.org/10.3390/risks12030055
Vancouver
Meng D, Metzler A, Reesor RM. Capital Structure Models and Contingent Convertible Securities. Risks. 2024;12(3):55. doi:10.3390/risks12030055
BibTeX
@article{Meng2024,
author = {Meng, Di and Metzler, Adam and Reesor, R. Mark},
title = {Capital Structure Models and Contingent Convertible Securities},
journal = {Risks},
year = {2024},
volume = {12},
number = {3},
pages = {55},
doi = {10.3390/risks12030055}
}
EUVIMED